Cramer Is Fond of Apple, Boeing, These 3 Stocks, Not So Keen on Lorillard

Jim Cramer made the following calls on August 14th, 2013. What do you think about his picks?

Apple Inc. (NASDAQ:AAPL): Jim Cramer ranked this stock a Buy. Cramer previously ranked this stock a Buy on July 31, 2013. The stock’s 52-week high is $705.07, and its 52-week low is $385.10.

After analysis of the stock’s chart last night, Cramer and colleague Carolyn Boroeden decided that Apple was indeed on the rise. A look a trends in the stocks movement indicated to Boroden that it could be enroute to $582 in the foreseeable future, and moving higher after that. Carl Ichan bought a substantial number of shares of the stock recently, helping to create a flurry of other buyers that sent the stock higher.

aapl-20130815

Boeing Co. (NYSE:BA): Jim Cramer ranked this stock a Buy. Cramer previously ranked this stock a Buy on July 19, 2013. The stock’s 52-week high is $109.49, and its 52-week low is $69.03.

Boeing, despite troubles with the 787 Dreamliner, continues to be a Cramer favorite, and he recommended it again to viewers last night as a stock that is resilient to a market environment where consumers are struggling. Boeing has just delivered 30 of its new 737-800′s to Iraqi Airways, the newest generation model of the 737.

BAa-20130815

CVS Caremark Corporation (NYSE:CVS): Jim Cramer ranked this stock a Buy. Cramer previously ranked this stock a Buy on July 31, 2013. The stock’s 52-week high is $62.36, and its 52-week low is $44.10.

CVS continues to catch Cramer’s eye, as he recommended the stock along side competitors Rite Aid (NYSE:RAD) and Walgreen Co. (NYSE:WAG). Speaking to viewers during the lightning round, he said that, “The group is strong. I happen to like CVS and Walgreen. There is a rising tide for the whole group. RAD is more expensive, but it is an okay situation, and Rite Aid is back.”

cvs-20130815

Immunogen Inc. (NASDAQ:IMGN): Jim Cramer ranked this stock a Buy. Cramer previously ranked this stock a Buy on July 1, 2013. The stock’s 52-week high is $20.25, and its 52-week low is $10.85.

Daniel Junius, president and CEO of Immunogen, sat down last night with Cramer to discuss the state of his business. Kadcyla, the companies newest approved cancer drug, it performing well, Junius said, and added that sales in Europe are still to come. Junius also defended drugs currently in testing from toxicity concerns, saying they were better than anything on the market.

imgn-20130815

Walgreen Co. (NYSE:WAG): Jim Cramer ranked this stock a Buy. Cramer previously ranked this stock a Buy on June 21, 2013. The stock’s 52-week high is $51.62, and its 52-week low is $31.88.

Walgreen was recommended along with the other two major chain pharmacies by Cramer last night during the lightning round. Walgreens increased sales in July by 8 percent to $6.03 billion, up from $5.59 billion last July.

wag-20130815

Lorillard, Inc. (NYSE:LO): Jim Cramer ranked this stock a Sell. Cramer previously ranked this stock a Buy on October 23, 2012. The stock’s 52-week high is $46.81, and its 52-week low is $36.70.

“I don’t want to buy these tobacco companies. They don’t give you the yield we need anymore,” so said Cramer last night during the lightning round when he shut down Lorillard. However, the company has experienced a healthy earnings increase in the second quarter, with diluted earnings per share up over 15 percent from last year.

lo-20130815

Don’t Miss: Will a Low-Cost Apple iPhone Hurt More Than Help?

More from The Cheat Sheet